 |
- American Society of Clinical Oncology (ASCO) has issued a new guideline for antimicrobial prophylaxis and outpatient management of fever and neutropenia (February 4, 2013)
- Sitafloxacin (GRACEVIT) now available in Thailand
Orally administered 50mg GRACEVIT (sitafloxacin) tablets entered the market in Thailand from March 5, 2012. Sitafloxacin, which belongs to the same class of drugs as levofloxacin, maintains remarkable microbiological eradication rates, even against highly resistant pathogens. (April 13, 2012)
- Review of treatments for MDR and XDR tuberculosis recommends high-dose levofloxacin (September 10, 2010)
- An American study shows that levofloxacin is more cost-effective than moxifloxacin for outpatient CAP treatment (December 18, 2009)
- Asian-Pacific Consensus Guidelines recommend levofloxacin for H. pylori infection (October 16, 2009)
- Gatifloxacin (TEQUIN) was withdrawn from sale
The FDA issued a notice to determine that TEQUIN (gatifloxacin) Tablets, Injection, and Oral Suspension, were withdrawn from sale for reasons of safety or effectiveness. (October 17, 2008)
- Moxifloxacin (AVELOX) and Serious Side Effects
Bayer has sent out letters warning European doctors about a number of reports of serious liver and skin side effects found in patients taking its fluoroquinolone antibiotic, AVELOX (March 17, 2008)
- FDA Panel Urges Limits on Telithromycin (KETEK)
The FDA advisory panel has concluded that telithromycin (KETEK) should not be sold to patients with sinusitis or bronchitis. It could still be used for mild to moderate pneumonia. (December 18, 2006)
|
